Mixed Dyslipidemia
📧 Sign up to get email alerts when something new happens for Mixed Dyslipidemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2009-05-13Clinical Trial Update: An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME) [Phase 3]
This completed Phase 3 open-label trial evaluated lipid-lowering effects of Niacin ER combined with Simvastatin versus Atorvastatin in adult…
-
CLINICAL_TRIALS trial_result · 2009-03-25Clinical Trial Update: Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood [Phase 3]
A Phase 3 trial evaluated the safety and efficacy of ABT-335 in combination with atorvastatin in subjects with mixed dyslipidemia and corona…
-
CLINICAL_TRIALS trial_result · 2009-03-25Clinical Trial Update: Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood [Phase 3]
Phase 3 trial evaluating safety and efficacy of ABT-335 in combination with rosuvastatin in subjects with multiple abnormal lipid levels has…
-
FDA approval · 2008-12-12FDA Approved: LIPOFEN — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Lipofen (fenofibrate) filed by ANI Pharmaceuticals, Inc., authorizing an update to the produ…
-
CLINICAL_TRIALS trial_result · 2008-08-21Clinical Trial Update: Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study [NA]
The DIACOR study evaluating diabetes and combined lipid therapy has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2008-06-05FDA Approved: ZETIA — Supplemental Application (Organon LLC)
The FDA approved a supplemental application for Zetia (ezetimibe) submitted by Organon LLC to update/expand aspects of its labeling.
-
FDA approval · 2008-06-03FDA Approved: FENOFIBRATE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for fenofibrate.
-
CLINICAL_TRIALS trial_result · 2008-05-07Clinical Trial Update: An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia
A completed clinical trial comparing simvastatin plus Omacor to simvastatin plus placebo in subjects with mixed dyslipidemia.
-
FDA approval · 2008-03-26FDA Approved: FENOFIBRATE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal Pharmaceuticals NY LLC's generic fenofibrate (ANDA 076509) as an original application, establishing equivalence to the r…
-
FDA approval · 2006-10-03FDA Approved: VYTORIN — Supplemental Application (Organon LLC)
The FDA approved a supplemental application for VYTORIN (ezetimibe and simvastatin) submitted by Organon LLC. This document confirms the app…
-
FDA approval · 2006-07-27FDA Approved: GEMFIBROZIL — Original Application (Exelan Pharmaceuticals, Inc.)
FDA approved the original application for a generic Gemfibrozil by Exelan Pharmaceuticals, enabling a generic version of Gemfibrozil to be m…
-
CLINICAL_TRIALS trial_result · 2006-06-28Clinical Trial Update: Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care [Phase 4]
Phase 4 efficacy trial comparing Extended-Release Niacin/Lovastatin to usual care in patients with lipid disorders. The study has completed.